Efficacy of MK615 for the treatment of patients with liver disorders

Table 3 Changes of serum level during MK615 therapy in patients with liver disorders

	Before therapy	During therapy 12 wk	P value1
WBC count (/μL)	4828 ± 1640	4977 ± 1855	NS
RBC count (104/μL)	436 ± 65	435 ± 65	NS
Hemoglobin (g/dL)	13.7 ± 2.0	13.8 ± 1.9	NS
Platelet count (104/μL)	15.7 ± 7.0	15.6 ± 6.6	NS
AST (IU/L)	94 ± 56	66 ± 35	< 0.05
ALT (IU/L)	104 ± 59	72 ± 39	< 0.05
γ-GTP (IU/L)	104 ± 121	74 ± 93	< 0.05
LDH (IU/L)	237 ± 52	227 ± 52	< 0.05
ALP (IU/L)	318 ± 124	298 ± 126	< 0.05
Total bilirubin (mg/dL)	0.8 ± 0.3	0.8 ± 0.3	NS
Total cholesterol (mg/dL)	170 ± 40	171 ± 43	NS
Total protein (g/dL)	7.6 ± 0.6	7.6 ± 0.5	NS
Albumin (g/dL)	4.0 ± 0.5	4.1 ± 0.4	NS
BUN (mg/dL)	15.5 ± 3.9	14.7 ± 3.5	NS
Creatinine (mg/dL)	0.75 ± 0.15	0.74 ± 0.15	NS

Data are expressed as the mean ± standard deviation.

¹Dunnett’s test. NS: Not significant; WBC: White blood cell; RBC: Red blood cell; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γ-GTP: γ-guanosine triphosphate; LDH: Lactate dehydrogenase; ALP: Alkaline phosphatase; BUN: Blood urea nitrogen; NS: Not significant.